In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

One of the closest-to-market among the 10 is mRNA-1283, a next-generation COVID vaccine. In his Monday letter, Bancel said the FDA has accepted Moderna’s application for the shot. Assisted by a ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

Moderna lost more than 20% of its value on the ... stressing savings as key to its goal of balancing cash flow by 2028. Ahead of CEO Stéphane Bancel’s address at the JP Morgan Healthcare ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says. Though most people recover from the ...